The FDA issued a third complete response letter for ONS-5010/Lytenava, requesting confirmatory efficacy evidence for wet AMD treatment. Lytenava is an ophthalmic bevacizumab formulation, potentially ...

Oraya Therapeutics Inc. announced today that leading ophthalmologists from three European countries presented patient results following one year after a single treatment with Oraya Therapy for wet age ...

Optometrists (healthcare providers who offer standard eye care) can diagnose wet age-related macular degeneration (AMD) but can't treat it. Therapies for wet AMD are primarily led by ophthalmologists ...

Both anti-VEGF and surgical treatments improve VA in AMD-related submacular hemorrhage, with no statistically significant difference between the two treatments. Anti-VEGF injections may be associated ...

Retinal diseases such as age-related macular degeneration (AMD) and diabetic retinopathy affect millions of people globally, often leading to vision loss with minimal straightforward treatment.

Age-Related Macular Degeneration (AMD) is the biggest cause of sight loss in the UK, affecting around 700,000 people. As ...

Aflibercept is a soluble decoy fusion protein that binds all isoforms of vascular endothelial growth factor (VEGF) with a greater binding affinity than ranibizumab. Intravitreal aflibercept is US Food ...

Researchers led by a team at the Wilmer Eye Institute, Johns Hopkins Medicine, have discovered why vision in some patients with neovascular (nv) or “wet” age-related macular degeneration (nvAMD, or ...

Continuous use of tear substitutes significantly improved dry eye symptoms in patients with neovascular age-related macular degeneration (AMD) who received frequent eye injections, whereas ...

Researchers at Science Tokyo developed an mRNA vaccine that suppressed abnormal retinal blood vessel growth in mouse models. The vaccine can be administered intramuscularly and showed effectiveness ...

Opthea is a clinical-stage biotech firm developing Sozinibercept, targeting VEGF-C and VEGF-D for wet AMD, with Phase 3 results due in 2025. The wet AMD market is lucrative, but the challenge lies in ...